Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

IMW 2019 | GMMG-HD4 and MM5: bortezomib vs. lenalidomide for myeloma maintenance

Elias Mai • 15 Sep 2019
IMW 2019
Multiple Myeloma Bortezomib Lenalidomide
GMMG-MM5 HOVON-65/GMMG-HD4

Elias Mai, MD, from the University Hospital Heidelberg, Heidelberg, Germany, talks about the GMMG-HD4 (NCT03617731) and MM5 (EudraCT no. 2010-019173-16) trials of bortezomib versus lenalidomide maintenance therapy for myeloma. This interview was recorded at the International Myeloma Workshop (IMW) 2019, held in Boston, MA.

More from Elias Mai

1:03
Advantages and applications of mass spectrometry in multiple myeloma
Elias Mai • 25 Apr 2023
1:31
The role of daratumumab in combination with lenalidomide as maintenance therapy in NDMM post-autoSCT
Elias Mai • 25 Apr 2023
1:05
Optimizing the treatment of transplant-eligible NDMM: using quadruplets in induction & consolidation
Elias Mai • 25 Apr 2023
0:49
An update on GMMG HD7: Isa-RVd vs RVd & lenalidomide-isatuximab vs lenalidomide maintenance in NDMM
Elias Mai • 9 Jun 2022

Related Videos

0:59
Looking forward to COMy 2024: celebrating 10 years
Mohamad Mohty • 17 Apr 2024
0:57
Overcoming barriers to treating older patients with myeloma
Sergio Giralt • 16 Apr 2024
1:01
The potentially curative role of CAR-T therapy in myeloma
Sergio Giralt • 16 Apr 2024
1:45
Expanded approval of cilta-cel in myeloma: the value of bringing CAR-T cells into earlier lines
Monika Engelhardt • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals